S Toma

Summary

Affiliation: University of Genoa
Country: Italy

Publications

  1. ncbi request reprint Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG)
    S Toma
    Department of Medical Oncology, University of Genoa National Institute for Cancer Research, Italy
    Anticancer Res 20:485-91. 2000
  2. ncbi request reprint Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patients
    S Toma
    Department of Oncology, Biology and Genetics, National Institute for Cancer Research, 16132 Genova, Italy
    Int J Oncol 17:991-1000. 2000
  3. ncbi request reprint RARalpha antagonist Ro 41-5253 inhibits proliferation and induces apoptosis in breast-cancer cell lines
    S Toma
    National Institute for Cancer Research, Department of Clinical and Experimental Oncology, University of Genoa, Italy
    Int J Cancer 78:86-94. 1998
  4. ncbi request reprint Retinoids in lung cancer chemoprevention and treatment
    S Toma
    Department of Medical Oncology, University of Genova, Italy
    Ann Oncol 10:S95-102. 1999
  5. ncbi request reprint Chemoprevention of tumors: the role of RAR-beta
    S Toma
    Department of Oncology, Biology and Genetics, University of Genoa, Italy
    Int J Biol Markers 18:78-81. 2003

Collaborators

Detail Information

Publications5

  1. ncbi request reprint Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG)
    S Toma
    Department of Medical Oncology, University of Genoa National Institute for Cancer Research, Italy
    Anticancer Res 20:485-91. 2000
    ..Few clinical trials in adult STS have been published until now, with disappointing and often contrasting results...
  2. ncbi request reprint Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patients
    S Toma
    Department of Oncology, Biology and Genetics, National Institute for Cancer Research, 16132 Genova, Italy
    Int J Oncol 17:991-1000. 2000
    ..Neither the ATRA + tamoxifen nor the ATRA + tamoxifen + interferon combinations potentiated the ATRA-induced biological changes. Future studies evaluating the role of RAR-beta as a biological marker of retinoid activity are warranted...
  3. ncbi request reprint RARalpha antagonist Ro 41-5253 inhibits proliferation and induces apoptosis in breast-cancer cell lines
    S Toma
    National Institute for Cancer Research, Department of Clinical and Experimental Oncology, University of Genoa, Italy
    Int J Cancer 78:86-94. 1998
    ..This retinoid antagonist seems to be a compound that exerts an anti-tumor activity but does not induce the toxic side effects of retinoids and might, therefore, be considered as a candidate for cancer therapy...
  4. ncbi request reprint Retinoids in lung cancer chemoprevention and treatment
    S Toma
    Department of Medical Oncology, University of Genova, Italy
    Ann Oncol 10:S95-102. 1999
    ..Such selective molecules may have a greater activity against lung cancer, with a more favourable toxicity profile, as recently suggested by our preliminary data on Ro 41-5253...
  5. ncbi request reprint Chemoprevention of tumors: the role of RAR-beta
    S Toma
    Department of Oncology, Biology and Genetics, University of Genoa, Italy
    Int J Biol Markers 18:78-81. 2003
    ..Transitions between successive stages can be enhanced or inhibited in the laboratory by different types of agents, such activities providing the fundamental basis for chemoprevention...